HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses
Owen, Rachel Ea,b; Heitman, John Wa; Hirschkorn, Dale Fa; Lanteri, Marion Ca; Biswas, Hope Ha; Martin, Jeffrey Nc; Krone, Melissa Rc; Deeks, Steven Gc; Norris, Philip Ja,b,d; the NIAID Center for HIV/AIDS Vaccine Immunology
aBlood Systems Research Institute, USA
bDepartments of Laboratory Medicine, USA
cEpidemiology and Biostatistics, USA
dMedicine, University of California, San Francisco, California, USA.
Received 29 July, 2009
Revised 21 December, 2009
Accepted 6 January, 2010
Correspondence to Blood Systems Research Institute, 270 Masonic Avenue, San Francisco, CA 94118, USA. Tel: +1 415 923 5769; fax: +1 415 567 5899; e-mail: email@example.com
Objective: HIV+ elite controllers are a unique group of rare individuals who maintain undetectable viral loads in the absence of antiretroviral therapy. We studied immune responses in these individuals to inform vaccine development, with the goal of identifying the immune correlates of protection from HIV.
Methods: We compared markers of cellular activation, HIV-specific immune responses and regulatory T (Treg) cell frequencies in four groups of individuals: HIV-negative healthy controls, elite controllers (HIV RNA level <75 copies/ml), individuals on HAART and individuals with HIV RNA level more than 10 000 copies/ml (noncontrollers).
Results: Elite controllers possessed significantly lower levels of activated HIV-specific CD8+ T cells and of recently divided HIV-specific CD4+ T cells than noncontrollers, whereas these differences were not seen in the respective cytomegalovirus-specific T-cell populations. Elite controllers also mounted a stronger and broader cytokine and chemokine response following HIV-specific stimulation than individuals on HAART and noncontrollers. Finally, we found that HAART-suppressed individuals had elevated Treg cell frequencies, whereas elite controllers and noncontrollers maintained normal percentages of Treg cells.
Conclusion: Elite controllers maintain high levels of HIV-specific immune responses with low levels of HIV-specific T-cell activation and do not have elevated Treg cell levels. Based on these data an ideal HIV vaccine would induce strong HIV-specific immune responses whereas minimizing HIV-specific T-cell activation.
HIV infection is characterized by chronic immune activation, uncontrolled viral replication and a loss of CD4+ T cells, resulting in progression to AIDS. A population of rare individuals (approximately 1% of the HIV-infected population) has been shown to maintain clinically undetectable plasma viral loads (<75 copies/ml) in the absence of therapy (‘elite controllers’) [1,2]. Elite controllers have decreased T-cell activation [3,4] and stronger HIV-specific CD4+ T-cell interferon-γ (IFNγ) and interleukin-2 responses targeted toward the Gag protein than individuals who do not control HIV replication .
It is well documented that there is an increase in the level of CD4+ and CD8+ T cells expressing ‘activation’ markers such as CD38, human leukocyte antigen-DR (HLA-DR) and/or Ki67 expression in HIV infection [3,6–9]. For reasons that have not yet been fully defined, a higher frequency of these cells is associated with more rapid disease progression, independent of viral load and CD4+ T-cell counts [3,10–12]. Recent studies by our group found that despite having undetectable viral loads, elite controllers had higher levels of immune activation than HIV seronegatives and HAART-suppressed individuals [2,3]. The mechanism accounting for this higher than expected level of immune activation is not known, but may be due to higher levels of HIV production, higher levels of microbial translocation, and/or lower levels of immunoregulatory cells.
As immune activation appears to play an adverse role in HIV infection, cells with the ability to decrease inflammation may be beneficial. Regulatory T (Treg) cells are a unique population of CD4+ T cells that have the ability to suppress the activation and proliferation of T cells [13–16]. This population of CD4+ T cells has traditionally been identified by the expression of CD25 and the transcription factor FoxP3, and more recently in combination with other markers including CD127 and CD152 [13,17–23]. Studies of the role of Treg cells in HIV infection show conflicting results. Some studies have shown an increase in the number of Treg cells in HIV infection [24–26], whereas others have shown a decrease [27–32]. Higher levels of Treg function could prevent some of the harmful effects of immune activation on disease progression, whereas lower levels could allow a strong and durable antigen-specific T-cell response.
Finally, cytokine and chemokine profiles may differ between elite controllers and noncontrollers. However, there is considerable variability in the levels of cytokines produced between infected individuals [33–38]. Studies of the earliest phase of HIV infection in plasma donors acquiring HIV revealed a striking pro-inflammatory cytokine cascade beginning within days of the first appearance of viremia [39,40]. Although there have been numerous studies of cytokine profiles in HIV infection, broad analysis of the cytokine responses in elite controllers has not been reported.
Despite strong and growing interest in the elite controllers as a model for understanding the optimal HIV-specific host response, no study to our knowledge has attempted to fully characterize the nature of the T-cell response in these individuals. In our current study we assessed the activation and proliferation status of antigen-specific CD4+ and CD8+ T cells, the cytokine and chemokine response to HIV and cytomegalovirus (CMV) stimulation, and the number of Treg cells in four groups of individuals. Our sample cohort included HIV seronegative individuals and three classes of HIV-infected individuals: elite controllers, HAART-suppressed individuals and noncontrollers. One sample from each individual was assessed for all parameters at the same time point, with the goal of identifying immunological factors that drive the maintenance of robust T-cell responses and control of viral replication in elite controllers in the absence of therapy.
Blood samples were obtained from HIV-infected individuals enrolled in the University of California, San Francisco (UCSF) SCOPE cohort and from 20 healthy HIV seronegative individuals. All individuals underwent informed consent under protocols approved by the UCSF Committee on Human Research. HIV-infected individuals were divided into three groups. (1) Elite controllers, at least two viral loads less than 75 copies/ml spanning 6 months or more (median of 10 undetectable viral loads/individual). A viral load more than 1000 copies were recorded in three individuals over 4.5 years prior to study sample acquisition. Three controllers had antiretroviral therapy (ART) exposure 7, 10 and 14 years prior to study. (2) HAART-suppressed, antiretroviral treated with at least two viral loads less than 75 copies/ml spanning 12 months or more. (3) Noncontrollers, untreated with an index viral load more than 10 000 copies/ml (Table 1). As advanced immunodeficiency can cause T-cell dysfunction, we excluded from our analysis any individual with a CD4+ T-cell count less than 300 cells/μl.
Stimulation of peripheral blood mononuclear cells
Cryopreserved peripheral blood mononuclear cells (PBMC) were rapidly thawed into RPMI supplemented with 10% heat-inactivated human AB serum (Sigma-Aldrich, St Louis, Missouri, USA), 10 mmol/l Hepes and 50 IU/ml penicillin/streptomycin (UCSF Cell Culture Facility). One million cells/well were stimulated in 96-well ‘U’ bottom plates (Falcon; BD Labware, Franklin Lakes, New Jersey, USA) for 1 h at 37°C, 5% carbon dioxide (CO2), with either 5 μg/ml of an HIV-1 p55 or CMV pp65 peptide pool (123 and 138 peptides, respectively, 15 amino acids long with 11 amino acid overlap, NIH AIDS Research and Reference Reagent Program), 200 ng/ml of staphylococcal enterotoxin B (SEB; Sigma-Aldrich) as a positive control, or were left unstimulated as a negative control. Brefeldin A (Sigma-Aldrich) and GolgiStop (BD Biosciences, San Jose, California, USA) were added together at final concentrations of 10 μg/ml and 8 μmol/l, respectively, prior to overnight incubation at 37°C, 5% CO2. Duplicate cultures without inhibitors were set up when cell numbers allowed for analysis of cytokines/chemokines. Supernatants were harvested between 18–24 h and frozen for batch analysis.
Flow cytometric analysis
Unless otherwise noted, all reagents were obtained from BD Pharmingen or BD Biosciences. Activation was assessed with the following panel: CD3-Pacific Blue, CD4-Alexa-fluor 700, CD8-APC-H7, CD45RA-PE-Cy5.5 (Caltag Laboratories, Burlingame, California, USA), CD27-APC, HLA-DR-PE-Cy5, CD38-PE, IFNγ-PE-Cy7, Ki67-fluorescein isothiocyanate (FITC) and aqua amine-reactive dye (Molecular Probes; Invitrogen, Carlsbad, California, USA). The Treg panel consisted of CD3-Pacific Blue, CD4-Alexa-fluor 700, CD25-PE-Cy7, CD127-PE, CD152-APC, FoxP3-Alexa-fluor 488 and aqua amine-reactive dye. Gating on CD4+CD25+CD127−CD152+ T cells has been shown to define Treg cells [18,19,23,41]. Our results were consistent with these prior studies showing that this population was also FoxP3+ (data not shown). Activation panel intracellular staining was accomplished using Cytofix and Cytoperm reagents (BD Biosciences) and Treg intracellular staining was performed using a Foxp3 staining buffer set (eBioscience, San Diego, California, USA) according to the respective manufacturer's instructions. Compensation controls included CompBeads or cells stained with equivalent quantities of test antibody. Fluorescence minus one (FMO) and isotype-stained controls were used to set gating. Gates for IFNγ were set using unstimulated negative control samples.
The Treg panel was acquired on an LSRII Flow Cytometer (BD Biosciences) and the activation panel on a FACS Aria (BD Biosciences). Instrument set-up was standardized to reduce batch-to-batch variation. Preoptimized target channel voltages were set using mid-range FL1 rainbow fluorescent particles (BD Biosciences). Single stained compensation tubes were checked to ensure each stain was the brightest in its own channel. A median of 150 000 viable CD3+ events was collected for each panel. Data were analyzed using FlowJo 8.7.3 software (TreeStar, Ashland, Oregon, USA).
Multiplex cytokine and chemokine analysis
Supernatants were assayed using the high-sensitivity LincoPlex kit (Millipore, Billerica, Massachusetts, USA) for interleukin-1β, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-10, interleukin-12 p70, interleukin-13, IFNγ, granulocyte-macrophage colony stimulating factor (GM-CSF) and tumor necrosis factor-α (TNFα), and the standard-sensitivity Milliplex Map kit (Millipore) for IFNα2, interleukin-15, interleukin-17, inducible protein-10, monocyte chemotactic protein-1 (MCP-1), MCP-3, macrophage derived chemokine (MDC), macrophage inflammatory protein-1α (MIP-1α), MIP-1β, sCD40L and TNFβ following the manufacturer's protocols. Samples were acquired on a Labscan 100 analyzer (Luminex, Austin, Texas, USA) using Bio-Plex manager 4.1 software (Bio-Rad, Hercules, California, USA).
Nonparametric tests were used because the data were not normally distributed. The Kruskal–Wallis test followed by Dunn's test for multiple comparisons was used to assess differences in the distribution of values for HIV seronegative individuals and infected groups. Spearman's rank test was used to determine the correlation between Treg number and age using Prism 5 software (Graphpad, La Jolla, California, USA). To examine the association between HAART therapy and the frequency of Treg cells, multivariate linear regression models were generated that included therapy (HAART therapy versus untreated), age and CD4+ T-cell count as independent variables using Stata 10.1 SE software (StataCorp LP, College Station, Texas, USA). Heat maps of the cytokine data were generated using Aabel 3 software (Gigawiz, Oklahoma City, Oklahoma, USA). Results were considered statistically significant if P less than 0.05.
Individuals from four groups were studied, HIV negatives, HIV elite controllers, HAART-suppressed and HIV noncontrollers, including 18 HIV elite controllers and 20 of each of the other groups. Most individuals were men, and the median age for the respective groups was 43, 48, 53 and 44 years (Table 1). The median CD4+ T-cell counts for the controllers, HAART-suppressed and noncontrollers were 764, 725 and 588 cells/μl (CD4+ T-cell counts were not available for the HIV seronegatives).
Elite controllers have the lowest levels of HIV-specific T-cell activation
For unclear reasons, at least a subset of elite controllers are able to maintain vigorous HIV-specific T-cell responses for extended periods, with some patients now known to be able to maintain control for up to 30 years. It is known that elite controllers have high frequencies of HIV-specific CD4+ and CD8+ T cells and intermediate levels of general T-cell activation when compared with HIV uninfected or HAART-suppressed individuals (low activation) and noncontrollers (high activation) [3,5], and we confirmed those findings in the current study (data not shown). However, we hypothesized that HIV-specific cells might be relatively less activated in elite controllers compared with noncontroller individuals. We defined activated HIV-specific cells as those co-expressing CD38 and HLA-DR (gated on IFNγ+ cells following HIV p55 stimulation, Fig. 1a). We found significantly lower levels of activated CD8+ but not CD4+ HIV-specific T cells among elite controllers and HAART-suppressed individuals compared with noncontrollers (Fig. 1b, c). Elite controllers also showed the lowest levels of recently divided HIV-specific CD4+ T cells (expressing Ki67), and their numbers were significantly lower than noncontrollers and HAART-suppressed individuals (Fig. 1d). There was no significant difference in the turnover of HIV-specific CD8+ T cells among the HIV+ groups (Fig. 1e).
The lower levels of HIV-specific CD8+ T-cell activation in elite controllers could have been due to decreased antigen exposure in individuals with lower viral load, as recently suggested [42–44]. To test this we measured activation of CMV-specific T cells and found no significant differences compared with noncontrollers (Fig. 2a, b). These results imply that the increased activation seen in HIV-specific CD8+ T cells from noncontrollers is due to greater antigenic stimulation compared with elite controllers. It has recently been suggested that CD4+ T-cell proliferation [measured by bromodeoxyuridine (BrdU) staining] is determined by both CD4+ T-cell depletion and HIV viral burden . One would expect that response to CD4+ T-cell depletion would occur equally in HIV-specific and CMV-specific CD4+ T-cells, whereas HIV viral burden would induce more proliferation in HIV-specific CD4+ T-cells in an antigen-specific fashion or equally affect HIV-specific and CMV-specific T cells through direct mechanisms such as infection of activated cells or induction of bystander apoptosis. Consistent with viral burden rather than CD4+ T-cell depletion driving proliferation, frequencies of recently divided CMV-specific T cells were lower compared with HIV-specific T cells among noncontrollers (P < 0.001 and P < 0.05 for CD4+ and CD8+ T cells, respectively). Additionally, the CMV-specific T cells showed no increase in recently divided cells in noncontrollers compared with elite controllers (Fig. 2c, d), illustrating no global increase in proliferation of antigen-specific cells in noncontrollers compared with elite controllers.
Elite controllers mount broad and vigorous HIV-specific cytokine responses
Elite control of HIV infection has been shown to correlate with the presence of cells able to secrete IFNγ, interleukin-2, TNFα and MIP-1β. We aimed to extend these observations by focusing on other factors that might be preferentially expressed in T cells from elite controllers. Stimulation with p55 induced pro-inflammatory cytokines and chemokines, including interleukin-2, IFNγ, TNFα, inducible protein-10, GM-CSF, MCP-3 and MIP-1β. PBMC from elite controllers produced significantly more IFNγ, GM-CSF, inducible protein-10, MCP-3, TNFα and interleukin-2 than the HIV seronegative individuals after p55 stimulation (Fig. 3a). In contrast, the HAART-suppressed group only produced significantly more IFNγ and inducible protein-10 upon p55 stimulation compared with the HIV seronegative individuals. The HAART-suppressed group also produced more interleukin-2 and interleukin-13 than the noncontrollers (Fig. 3a). The noncontrollers produced the lowest levels of HIV-induced cytokines, only secreting IFNγ and inducible protein-10 (Fig. 3a). The noncontrollers had the lowest mean-fold increase in IFNγ compared with elite controllers and HAART-suppressed individuals (mean-fold change of 31.69 versus 424.23 for elite controllers and 246.50 for HAART-suppressed). The noncontrollers also secreted less TNFα, GM-CSF and MCP-3 than the elite controllers (Fig. 3a). Collectively, these data demonstrate the elite controllers can produce a wide breadth of cytokines and chemokines after HIV stimulation, including antiviral factors such as MIP-1β.
Stimulation of PBMC with the CMV pp65 peptide pool induced cytokines and chemokines to the same degree in all groups, with the exception of noncontrollers who produced significantly less MDC than HIV seronegative individuals and less GM-CSF than HAART-suppressed individuals (Fig. 3b). Therefore, the alterations in the cytokine and chemokine environment were HIV-specific and not a result of general immune activation resulting from a chronic viral infection.
Elite controllers have no elevation in the number of regulatory T cells
The decreased levels of activation and proliferation seen in HIV-specific T cells from elite controllers may have been due to higher magnitude Treg cell levels in the elite controllers. We defined Treg cells as CD4+CD25+CD127−CD152+ (Fig. 4a). The frequency and absolute number of these cells in the elite controllers were comparable with that in HIV seronegatives and noncontrollers, whereas the HAART-suppressed patients showed an elevated percentage of Treg cells compared with HIV seronegatives and elevated absolute Treg cell numbers compared with noncontrollers (Fig. 4b, c). We found no significant correlation between individual age and absolute Treg cell count among HIV+ samples (Fig. 4d). However, when all samples (both HIV+ and HIV−) were analyzed, a positive correlation between the frequency of Treg cells and age was found (data not shown, P < 0.05). The HAART-suppressed group, which had the highest frequency and absolute number of Treg cells, also had the oldest median age of 53 years (range 35–80 years), significantly older than the median age of the HIV seronegative individuals and the HIV+ noncontrollers (Table 1, P < 0.05 for both comparisons). Multivariable linear regression analysis showed that after adjusting for age and CD4+ cell count, HAART was significantly associated with a 0.60% increase in the frequency of Treg cells on average (P = 0.03). Age (P = 0.63) and CD4 cell count (P = 0.60) were not significantly associated with an increase in the frequency of Treg cells.
We found that elite controllers maintained lower levels of activated HIV-specific CD8+ and recently divided HIV-specific CD4+ T cells compared with noncontrollers, and this was not explained by increased proportions of Treg cells in elite controllers. Decreased antigen-specific T-cell activation was limited to the HIV-specific subsets of cells and was not found in the respective CMV-specific populations. Additionally, the elite controllers possessed the strongest and broadest HIV-specific immune responses, with seven cytokines and chemokines induced by HIV stimulation (interleukin-2, IFNγ, TNFα, GM-CSF, inducible protein-10, MCP-3 and MIP-1β). In summary, elite controllers maintained the strongest HIV-specific immune responses, with markers of inflammation on HIV-specific cells significantly lower than those in individuals unable to control viral replication.
Elite controllers had the ability to mount a strong and broad antiviral cytokine response when stimulated with a p55 peptide pool, producing interleukin-2, IFNγ, TNFα, inducible protein-10, GM-CSF, MIP-1β and MCP-3. Although the noncontrollers also induced some of the same cytokines as elite controllers (interleukin-2, IFNγ, TNFα, GM-CSF, inducible protein-10 and MCP-3), they produced significantly less of each than elite controllers. The lower quantities of antiviral cytokines may reflect weak antiviral T-cell responses and be associated with exhaustion of adaptive immune responses. ART was clearly associated with a reduced ability to secrete a broad cytokine and chemokine response, with these individuals only secreting significant amounts of interleukin-2, IFNγ and inducible protein-10. Interestingly, HAART suppression was associated with the production of interleukin-13, a cytokine involved in B cell growth and differentiation that can inhibit macrophage inflammatory cytokine production. The reduction of inflammatory cytokines could also be responsible for the reduction in T-cell activation and proliferation seen during HAART treatment. Our multiplex cytokine testing data support previous reports of viral control being associated with polyfunctional T-cell responses [42,45,46], and the cytokines identified above further clarify which specific responses are associated with control of viral replication during chronic HIV infection.
The increase in the number of Treg cells following HAART that we observed is consistent with some previous studies. Weiss et al. found an expanded number of Treg cells in HIV+ individuals receiving HAART, with a Treg cell phenotype similar to that of normal donors and cancer patients . Lim et al. also observed an increase in the number of Treg cells identified by an increase in FoxP3 mRNA expression in individuals who suppressed viremia with HAART . Kolte et al. found that both absolute Treg cell numbers and the percentage of Treg cells were increased after 1 and 5 years of receiving HAART and were associated with an increase in the thymic output of naive Treg cells . Two other studies showed no effect of HAART on Treg cell numbers despite suppression of viral replication and immunological recovery [49,50]. The precise mechanism of Treg cell expansion during HAART remains unknown and requires further investigation. An increase in the peripheral Treg cell pool by proliferation, increased survival of Treg cells or an increase in the thymic generation of Treg cells all could be responsible [41,51–53]. As we saw no correlation between the number of Treg cells and HIV-specific or CMV-specific T-cell responses (data not shown), it would appear that Treg cells do not strongly interfere with HIV-specific immune responses, raising the possibility of inducing these cells to ameliorate the effects of immune activation in the setting of high viral loads during chronic HIV infection.
Although our data mostly agree with those of Chase et al. , we did see a difference in which HIV-infected group had the highest number of Treg cells. Elite controllers in the Chase et al. study had the highest number of Treg cells, whereas we saw the highest number of Treg cells in our HAART-suppressed group. One possible explanation for this is confounding by age, as older individuals have higher Treg cell numbers [55–57]. In both our study and the Chase study the groups with the highest number of Treg cells were also the oldest. In the Chase study elite controllers were the oldest (median age = 54 years), whereas their HAART-suppressed group was the youngest (median age = 46 years). In contrast, our HAART-suppressed group was the oldest (median age = 53 years) and the elite controllers were younger (median age = 48 years). Multivariate analysis of our data, which controlled for confounding by age, showed that the increase in Treg cells was due to the therapy and not age. Whether this would be the case in the Chase et al. study  was not addressed.
In conclusion, lower levels of HIV-specific T-cell activation and in-vivo proliferation combined with stronger, broader HIV-specific cytokine responses likely play a role in the control of HIV infection by elite controllers. However, elite controllers do not completely clear the virus  and may eventually lose their elite status and progress toward the development of AIDS [1,3]. A therapeutic vaccine or immune modulation that could reduce immune activation, potentially by the induction of Treg cells, and generate a more appropriate balance of immune responses (such as those seen in elite controllers) may allow noncontrollers to decrease HIV replication and delay the progression to AIDS.
The present study was supported in part by grants from the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI) AI-067854, the UCSF/Gladstone Center for AIDS Research (P30 AI27763, NIAID (AI069994, AI44595), the UCSF Clinical and Translational Science Institute (UL1 RR024131-01) and American Foundation for AIDS Research (106710-40-RGRL).
The following reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NAID, NIH: HIV-1 consensus B Gag peptides (#8117), HCMV pp65 peptide pool (#11549). The UCSF AIDS Specimen Bank provided cryopreserved PBMC from the SCOPE cohort. We thank P.W. Hunt and J.M. McCune for helpful discussions.
1. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406–416.
2. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009; 83:329–335.
3. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126–133.
4. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 2007; 104:6776–6781.
5. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79:14169–14178.
6. Almeida M, Cordero M, Almeida J, Orfao A. Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients. Cytometry B Clin Cytom 2007; 72:22–33.
7. Benito JM, Lopez M, Lozano S, Ballesteros C, Martinez P, Gonzalez-Lahoz J, Soriano V. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38:373–381.
8. Kestens L, Vanham G, Vereecken C, Vandenbruaene M, Vercauteren G, Colebunders RL, Gigase PL. Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994; 95:436–441.
9. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:83–92.
10. Eggena MP, Barugahare B, Okello M, Mutyala S, Jones N, Ma Y, et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. J Infect Dis 2005; 191:694–701.
11. Fernandez S, Price P, McKinnon EJ, Nolan RC, French MA. Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function. Clin Immunol 2006; 120:163–170.
12. Kolber MA. CD38+CD8+ T-cells negatively correlate with CD4 central memory cells in virally suppressed HIV-1-infected individuals. AIDS 2008; 22:1937–1941.
13. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330–336.
14. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10:801–805.
15. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and nonself. Nat Immunol 2005; 6:345–352.
16. Suvas S, Kumaraguru U, Pack CD, Lee S, Rouse BT. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med 2003; 198:889–901.
17. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 2001; 167:1245–1253.
18. Hartigan-O'Connor DJ, Poon C, Sinclair E, McCune JM. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods 2007; 319:41–52.
19. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006; 203:1701–1711.
20. Ndhlovu LC, Loo CP, Spotts G, Nixon DF, Hecht FM. FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection. J Leukoc Biol 2008; 83:254–262.
21. O'Garra A, Vieira P. Twenty-first century Foxp3. Nat Immunol 2003; 4:304–306.
22. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151–1164.
23. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192:303–310.
24. Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006; 108:3808–3817.
25. Tenorio AR, Martinson J, Pollard D, Baum L, Landay A. The relationship of T-regulatory cell subsets to disease stage, immune activation, and pathogen-specific immunity in HIV infection. J Acquir Immune Defic Syndr 2008; 48:577–580.
26. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004; 104:3249–3256.
27. Baker CA, Clark R, Ventura F, Jones NG, Guzman D, Bangsberg DR, Cao H. Peripheral CD4 loss of regulatory T cells is associated with persistent viraemia in chronic HIV infection. Clin Exp Immunol 2007; 147:533–539.
28. Chase AJ, Sedaghat AR, German JR, Gama L, Zink MC, Clements JE, Siliciano RF. Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol 2007; 81:12748–12757.
29. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol 2005; 174:4407–4414.
30. Jiang Q, Zhang L, Wang R, Jeffrey J, Washburn ML, Brouwer D, et al. FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo. Blood 2008; 112:2858–2868.
31. Jiao Y, Fu J, Xing S, Fu B, Zhang Z, Shi M, et al. The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8(+) T cells in HIV-1-infected typical progressors, but not in long-term nonprogressors. Immunology 2008; 128(Suppl 1):e366–e375.
32. Mozos A, Garrido M, Carreras J, Plana M, Diaz A, Alos L, et al. Redistribution of FOXP3-positive regulatory T cells from lymphoid tissues to peripheral blood in HIV-infected patients. J Acquir Immune Defic Syndr 2007; 46:529–537.
33. Barcellini W, Rizzardi GP, Borghi MO, Fain C, Lazzarin A, Meroni PL. TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS 1994; 8:757–762.
34. Fan J, Bass HZ, Fahey JL. Elevated IFN-gamma and decreased IL-2 gene expression are associated with HIV infection. J Immunol 1993; 151:5031–5040.
35. Graziosi C, Pantaleo G, Gantt KR, Fortin JP, Demarest JF, Cohen OJ, et al. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 1994; 265:248–252.
36. Klein SA, Dobmeyer JM, Dobmeyer TS, Pape M, Ottmann OG, Helm EB, et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 1997; 11:1111–1118.
37. Miedema F, Petit AJ, Terpstra FG, Schattenkerk JK, de Wolf F, Al BJ, et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 1988; 82:1908–1914.
38. Vyakarnam A, Matear P, Meager A, Kelly G, Stanley B, Weller I, Beverley P. Altered production of tumour necrosis factors alpha and beta and interferon gamma by HIV-infected individuals. Clin Exp Immunol 1991; 84:109–115.
39. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP. Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 2006; 22:757–762.
40. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viraemia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83:3719–3733.
41. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693–1700.
42. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781–4789.
43. Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A 2008; 105:19851–19856.
44. Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, Meier A, et al. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 2008; 5:e100.
45. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:11983–11991.
46. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, et al. Mucosal immune responses to HIV-1 in elite controllers: A potential correlate of immune control. Blood 2009; 113:3978–3989.
47. Lim A, Tan D, Price P, Kamarulzaman A, Tan HY, James I, French MA. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. AIDS 2007; 21:1525–1534.
48. Kolte L, Gaardbo JC, Skogstrand K, Ryder LP, Ersboll AK, Nielsen SD. Increased levels of regulatory T cells (Tregs) in human immunodeficiency virus-infected patients after 5 years of highly active antiretroviral therapy may be due to increased thymic production of naive Tregs. Clin Exp Immunol 2009; 155:44–52.
49. Gaardbo JC, Nielsen SD, Vedel SJ, Ersboll AK, Harritshoj L, Ryder LP, et al. Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active antiretroviral therapy. Clin Exp Immunol 2008; 154:80–86.
50. Lim AY, Price P, Beilharz MW, French MA. Cell surface markers of regulatory T cells are not associated with increased forkhead box p3 expression in blood CD4+ T cells from HIV-infected patients responding to antiretroviral therapy. Immunol Cell Biol 2006; 84:530–536.
51. Akbar AN, Vukmanovic-Stejic M, Taams LS, Macallan DC. The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat Rev Immunol 2007; 7:231–237.
52. Antons AK, Wang R, Oswald-Richter K, Tseng M, Arendt CW, Kalams SA, Unutmaz D. Naive precursors of human regulatory T cells require FoxP3 for suppression and are susceptible to HIV infection. J Immunol 2008; 180:764–773.
53. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 2005; 115:1953–1962.
54. Chase AJ, Yang HC, Zhang H, Blankson JN, Siliciano RF. Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol 2008; 82:8307–8315.
55. Kozlowska E, Biernacka M, Ciechomska M, Drela N. Age-related changes in the occurrence and characteristics of thymic CD4(+) CD25(+) T cells in mice. Immunology 2007; 122:445–453.
56. Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 2007; 188:117–127.
57. Tenorio AR, Spritzler J, Martinson J, Gichinga CN, Pollard RB, Lederman MM, et al. The effect of aging on T-regulatory cell frequency in HIV infection. Clin Immunol 2009; 130:298–303.
activation; cellular immunity; HIV; pathogenesis; regulatory T cells
© 2010 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.